



# Science Report 2016



[www.profil.com](http://www.profil.com)



**Dr Tim Heise**  
Lead Scientist  
Chairman of the Board of Directors  
Co-Founder Profil Germany

## Preface

I am very proud to present the Profil Science Report 2016. As in the last years, our Science Report impressively documents the sound scientific expertise standing of Profil Germany. With 45 scientific publications (cumulated impact factor of > 187) and more than 100 scientific presentations at international meetings, our publication record at Profil Germany can easily compete with that of many academic institutions.

The extensive list of our publications in 2016 strengthens the scientific reputation of Profil Germany. We have a proven track record for outstanding presentations of clinical trial results to both the scientific and the business world as well as to boards and regulatory bodies. We are convinced that scientific (in combination with regulatory) expertise is key for optimally designing and conducting clinical studies, and therefore is the basis for the high client satisfaction that we are so proud of.

In addition, we are much obliged to the many people with type 1 or type 2 diabetes that participate in our studies and thereby make a huge contribution to the development of better drugs and devices for the treatment of diabetes and obesity. In order to get the best possible result from their efforts, we are committed to making the results of our studies available to the scientific community.

We look very much forward to interacting with patients, physicians, scientists and people from industry to continue and further expand our scientific activities in the next couple of years. We will not relent in our efforts to serve our customers' needs even better and to make our small contribution for a better life of people with diabetes all over the world.



# Content

Science Report 2016 .....	1
Content .....	3
Metrics .....	4
Scientific Publications .....	6
Original Articles .....	6
Reviews.....	12
Letters / Comments .....	14
Scientific Presentations.....	15
Oral Presentations .....	15
Poster Presentations .....	24
Advanced Training Courses.....	30
Science Sessions .....	30
Trainings with External Participants .....	31
Granted Research Consortia .....	32
Scientific Communication.....	35
Webinars .....	35
Blogs .....	36
Media Reports (Selection).....	38

# Metrics

**TABLE 1: TOTAL OUTPUT**

	Count	$\Sigma$ Impact Factors	Mean Impact Factor
<b>Scientific Publications</b>	<b>45</b>	<b>187,573</b>	<b>5,684</b>
Original Articles	31	139,566	5,583
Reviews	13	30,110	4,301
Letters/Comments	1	17,897	17,897
<b>Scientific Congress Presentations</b>	<b>106</b>	n/a	n/a
Orals	70	n/a	n/a
Poster	36	n/a	n/a
<b>Advanced Trainings</b>	<b>7</b>	n/a	n/a
<b>Granted Research Consortia</b>	<b>4</b>	n/a	n/a
<b>Scientific Communication</b>	<b>55+</b>	n/a	n/a
Webinars	8	n/a	n/a
Blogs	19	n/a	n/a
Media Reports	28+	n/a	n/a

**TABLE 2: PROFIL SCIENTIST(S) FIRST/SENIOR AUTHOR**

	Count	$\Sigma$ Impact Factors	Mean Impact Factor
<b>Scientific Publications</b>	<b>30</b>	<b>119,376</b>	<b>5,190</b>
Original Articles	16	71,369	4,758
Reviews	14	30,110	4,301
Letters/Comments	1	17,897	17,897
<b>Scientific Congress Presentations</b>	<b>97</b>	n/a	n/a
Orals	69	n/a	n/a
Poster	28	n/a	n/a

**TABLE 3: STUDIES (PARTLY) OPERATED BY PROFIL**

	Count	$\Sigma$ Impact Factors	Mean Impact Factor
<b>Scientific Publications</b>	<b>26</b>	<b>130,089</b>	<b>5,656</b>
Original Articles	26	130,089	5,656
Reviews	n/a	n/a	n/a
Letters/Comments	n/a	n/a	n/a
<b>Scientific Congress Presentations</b>	<b>56</b>	n/a	n/a
Orals	21	n/a	n/a
Poster	35	n/a	n/a

**TABLE 4: STUDIES (PARTLY) OPERATED BY PROFIL**
**+ PROFIL SCIENTIST(S) FIRST/SENIOR AUTHOR**

	Count	$\Sigma$ Impact Factors	Mean Impact Factor
<b>Scientific Publications</b>	<b>16</b>	<b>71,369</b>	<b>4,758</b>
Original Articles	16	71,369	4,758
Reviews	n/a	n/a	n/a
Letters/Comments	n/a	n/a	n/a
Book Chapters	n/a	n/a	n/a
Books	n/a	n/a	n/a
<b>Scientific Congress Presentations</b>	<b>47</b>	n/a	n/a
Orals	20	n/a	n/a
Poster	27	n/a	n/a

# Scientific Publications

## Original Articles

1. Kuhlenkötter, M., Heise, T., Benesch, C.  
Improved algorithm for automated glucose clamps.  
**Diabetes Technol. Ther.**, accepted  
**IF(2015): 2.198**
2. Forst, T., Falk, A., Andersen, G., Fischer, A., Weber, M.M., Voswinkel, S.,  
Heise, T., Kapitza, C., Plum-Mörschel, L.  
Effects of sequentially adding empagliflozin and linagliptin on alpha and beta cell function in type 2 diabetic patients on previous metformin treatment – an exploratory mechanistic study.  
**Diabetes Obes. Metab.**, accepted  
**IF(2015): 6.198**
3. Famulla, S., Pieber, T.R., Eilbracht, J., Neubacher, D., Soleymanlou, N., Woerle, H.J., Broedl, U.C. Kaspers, S.  
Glucose exposure and variability with empagliflozin as adjunct to insulin in patients with type 1 diabetes: continuous glucose monitoring data from a 4-week, randomized, placebo-controlled trial (EASE-1).  
**Diabetes Technol. Ther.**, accepted  
**IF(2015): 2.198**
4. Kann, P.H., Moll, R., Bartsch, D., Pfützner, A., Forst, T., Tamagno, G., Goebel, J.N., Fourkiotis, V., Bergmann, S.R., Collienne, M.  
Endoscopic ultrasound-guided fine needle aspiration biopsy (EUS-FNA) in insulinomas: indications and clinical relevance in a single investigator cohort of 47 patients.  
**Endocrine** PMID: 27905047, 2016  
**IF(2015): 3.279**
5. Porksen, N., Linnebjerg, H., Garhyan, P., Lam, E.C., Knadler, M.P., Jacober, S.J., Hövelmann, U., Plum-Mörschel, L., Watkins, E., Gastaldelli, A., Heise, T.  
Novel hepato-preferential basal insulin pglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes.  
**Diabetes Obes. Metab.**, PMID: 27888561, 2016  
**IF(2015): 6.198**

6. Heise, T., Stender-Petersen, K., Hövelmann, U., Jacobsen, J.B., Nosek, L., Zijlstra, E., Haahr, H.  
 Pharmacokinetic and pharmacodynamic properties of faster-acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus.  
**Clin. Pharmacokinet.**, PMID: 27878566, 2016  
**IF(2015): 4.829**
7. Heise, T., Hövelmann, U., Zijlstra, E., Stender-Petersen, K., Jacobsen, J.B., Haahr, H.  
 A comparison of pharmacokinetic and pharmacodynamic properties between faster-acting insulin aspart and insulin aspart in elderly subjects with type 1 diabetes mellitus.  
**Drugs Aging**, PMID: 27873152, 2016  
**IF(2015): 2.610**
8. Kropff, J., Choudhary, P., Neupane, S., Barnard, K., Bain, S.C., Kapitza, C., Forst, T., Link, M., Dehennis, A., DeVries, J.H.  
 Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial.  
**Diabetes Care**, PMID: 27815290, 2016  
**IF(2015): 8.934**
9. Zijlstra, E., Heinemann, L., Fischer, A., Kapitza, C.  
 A comprehensive performance evaluation of five blood glucose systems in the hypo-, eu-, and hyperglycemic range.  
**J. Diabetes Sci. Technol.** 10(6): 1316-1323, 2016  
**IF(2015): -**
10. Heise, T., Zijlstra, E., Nosek, L., Rikte, T., Haahr, H.  
 Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: a randomized, double-blind, crossover trial.  
**Diabetes Obes. Metab.**, PMID: 27815290, 2016  
**IF(2015): 6.198**
11. Heise, T., Jordan, J., Wanner, C., Heer, M., Macha, S., Mattheus, M., Lund, S.S., Woerle, H.J., Broedl, U.C.  
 Pharmacodynamic effects of single and multiple doses of empagliflozin in patients with type 2 diabetes.  
**Clin. Ther.**, 38(10): 2256-2276, 2016  
**IF(2015): 2.925**

12. Heise, T., Jordan, J., Wanner, C., Heer, M., Macha, S., Mattheus, M., Lund, S.S., Woerle, H.J., Broedl, U.C.  
 Acute pharmacodynamic effects of empagliflozin with and without diuretic agents in patients with type 2 diabetes mellitus.  
**Clin Ther.**, 38(10): 2248-2264, 2016  
**IF(2015): 2.925**
13. Heise, T., Korsatko, S., Nosek, L., Coester, H.V., Deller, S., Roepstorff, C., Segel, S., Kapur, R., Haahr, H., Hompesch, M.  
 Steady state is reached within two to three days of once-daily administration of degludec, a basal insulin with an ultra-long duration of action.  
**J. Diabetes** 8(1): 132-138  
**IF(2015): 2.500**
14. Jordan, J., Stinkens, R., Jax, T., Engeli, S., Blaak, E.E., May, M., Havekes, B., Schindler, C., Albrecht, D., Pal, P., Heise, T., Goossens, G.H., Langenickel, T.H.  
 Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension.  
**Clin. Pharmacol. Ther.**, PMID: 27542885, 2016  
**IF(2015): 7.268**
15. Linnebjerg, H., Lam, E.C., Zhang, X., Seger, M.E., Coutant, D., Chua, L., Kapitza, C., Heise, T.  
 Duration of action of two insulin glargine products, LY2963016 insulin glargine and lantus insulin glargine, in subjects with type 1 diabetes mellitus.  
**Diabetes Obes. Metab.**, PMID: 27484286, 2016  
**IF(2015): 6.198**
16. Famulla, S., Hövelmann, U., Fischer, A., Coester, H.V., Hermanski, L., Kaltheuner, M., Kaltheuner, L., Heinemann, L., Heise, T., Hirsch L.  
 Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action and impaired postprandial glucose control.  
**Diabetes Care** 39(9): 1486-1492, 2016  
**IF(2015): 8.934**
17. Leelarathna, L., Thabit, H., Harthell, S., Willinska, M.E., Dellweg, S., Benesch, C., Mader, J.K., Holzer, M., Kojzar, H., Evans, M.L., Arnolds, S., Pieber, T.R., Hovorka R., AP@home Consortium.  
 Rapid benefits of structured optimization and sensor-augmented insulin pump therapy in adults with type 1 diabetes.  
**J. Diabetes Sci. Technol.**, PMID: 27328806, 2016  
**IF(2015): -**

18. Lind, M., Polonsky, W., Hirsch, I.B., Heise, T., Bolinder, J., Dahlqvist, S., Pehrsson, N.G., Moström, P.  
 Design and methods of a randomized trial of continuous glucose monitoring in persons with type 1 diabetes with impaired glycemic control treated with multiple daily insulin injections (GOLD Study).  
**J. Diabetes Sci. Technol.** 10(3): 754-761, 2016  
IF(2015): -
19. Ruan, Y., Thabit, H., Leelarathna, L., Hartnell, S., Willinska, M.E., Dellweg, S., Benesch, C., Mader, J.K., Holzer, M., Kojzar, H., Evans, M.L., Pieber, T.R., Arnolds, S., Hovorka, R., AP@home Consortium.  
 Variability of insulin requirements over 12 weeks of closed-loop insulin delivery in adults with type 1 diabetes.  
**Diabetes Care** 39(5): 830-832, 2016  
IF(2015): 8.934
20. Ferrannini, E., Baldi, S., Frascerra, S., Astiarraga, B., Heise, T., Bizzotto, R., Mari, A., Pieber, T.R., Muscelli, E.  
 Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes.  
**Diabetes** 65(5): 1190-1195, 2016  
IF(2015): 8.784
21. Freude, S., Heise, T., Woerle, H.J., Jungnik, A., Rauch, T., Hamilton, B., Schölch, C., Huang, F., Graefe-Mody, U.  
 Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11beta-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11beta-HSD1 inhibition after acute and multiple administrations over 2 weeks.  
**Diabetes Obes. Metab.** 18(5): 483-490, 2016  
IF(2015): 6.198
22. Muscelli, E., Astiarraga, B., Barsotti, E., Mari, A., Schliess, F., Nosek, L., Heise, T., Broedl, U.C., Woerle, H.J., Ferrannini, E.  
 Metabolic consequences of acute and chronic empagliflozin administration in treatment-naïve and metformin pretreated patients with type 2 diabetes.  
**Diabetologia** 59(4): 700-708, 2016  
IF(2015): 6.206
23. Stirban, A.O., Andjelkovic, M., Heise, T., Nosek, L., Fischer, A., Gastaldelli, A., Herz, M.  
 Aleglitazar, a dual peroxisome proliferator-activated receptor-alpha/gamma agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.  
**Diabetes Obes. Metab.** 18(7):711-715, 2016  
IF(2015): 6.198

24. Forst, T., Michelson, G., Diessel, S., Jahnke, J., Kapitza, C.  
Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients.  
**J. Hypertens.** 34(2): 345-350, 2016  
**IF(2015): 5.062**
25. Heise, T., Bain, S.C., Bracken, R.M., Zijlstra, E., Nosek, L., Stender-Petersen, K., Rabøl, R., Rowe, E., Haahr, H.L.  
Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial.  
**Diabetes Obes. Metab.** 18(2): 196-199, 2016  
**IF(2015): 6.198**
26. Marquard, J., Stirban, A.O., Schliess, F., Sievers, F., Welters, A., Otter, S., Fischer, A., Wnendt, S., Meissner, T., Heise, T., Lammert, E.  
Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial.  
**Diabetes Obes. Metab.** 18(1): 100-103, 2016  
**IF(2015): 6.198**
27. Blauw, H., Wendl, I., DeVries, J.H., Heise, T., Jax, T., PCDIAB consortium.  
Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels.  
**Diabetes Obes. Metab.** 18(1): 100-103, 2016  
**IF(2015): 6.198**
28. Levin, P.A., Heinemann, L., Boss, A., Rosenblit, P.D.  
Impact of symptomatic upper respiratory tract infections on insulin absorption and action of Technosphere inhaled insulin.  
**BMJ Open Diabetes Res. Care**, PMID: 27648286, 2016  
**IF(2015): -**
29. Siegmund, T., Pfohl, M., Forst, T., Pscherer, S., Bramlage, P., Foersch, J., Borck, A., Seufert, J.  
Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment - a prospective observational study in 2202 patients.  
**Diabetes Metab. Syndr.** PMID: 27578616, 2016  
**IF(2015): -**
30. Leiter, L.A., Forst, T., Polidori, D., Balis, D.A., Xie, J., Sha, S.  
Effect of canagliflozin on liver function tests in patients with type 2 diabetes.  
**Diabetes Metab.** 42(1): 25-32, 2016  
**IF(2015): 4.693**



31. Fulcher, G., Matthews, D.R., Perkovic, V., de Zeeuw, D., Mahaffey, K.W., Mathieu, C., Woo, V., Wysham, C., Capuano, G., Desai, M., Shaw, W., Vercruyse, F., Meininger, G., Neal, B., CANVAS trial collaborative group. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.  
**Diabetes Obes. Metab.** 18(1): 82-91.  
**IF(2015): 6.198**

## Reviews

32. Heise, T., Zijlstra, E., Nosek, L., Heckermann, S., Plum-Mörschel, L., Forst, T.  
Euglycaemic glucose clamp: what it can and cannot do, and how to do it.  
**Diabetes Obes Metab.** 18(10): 962-972, 2016  
**IF(2015): 6.198**
33. Maahs, D.M., Buckingham, B.A., Castle, J.R., Cinar, A., Damiano, E.R., Dassau, E., DeVries, J.H., Doyle, F.J. 3rd, Griffen, S.C., Haidar, A., Heinemann, L., Hovorka, R., Jones, T.W., Kollman, C., Kovatchev, B., Levy, B.L., Nimri, R., O'Neal D.N., Philip, M., Renard, E., Russell, S.J., Weinzimer, S.A., Zisser, H., Lum, J.W. Outcome measures for Artificial Pancreas clinical trials: a consensus report.  
**Diabetes Care** 39(7): 1175-1179, 2016.  
**IF(2015): 8.934**
34. Heinemann, L., Benesch, C., DeVries, J.H., AP@home Consortium.  
AP@home: the Artificial Pancreas is now at home.  
**J. Diabetes Sci. Technol.** 10(4): 950-958, 2016  
**IF(2015): -**
35. Haahr, H., Fita, E.G., Heise, T.  
A review of insulin degludec/insulin aspart: pharmacokinetic and pharmacodynamic properties and their implications in clinical use.  
**Clin. Pharmacokinet.**, PMID: 27696221, 2016  
**IF(2015): 4.829**
36. Heise, T., Mathieu, C.  
Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes.  
**Diabetes Obes. Metab.**, PMID: 27593206  
**IF(2015): 6.198**
37. Forst, T., Heise, T., Plum-Morschel, L.  
Pharmacological intervention in type 2 diabetes mellitus - a pathophysiological reasoned approach?  
**Curr. Diabetes Rev.** 12(4): 429-439, 2016  
**IF(2015): -**
38. Forst, T.  
Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus.  
**Expert Opin. Pharmacother.** 17(12): 1703-1708, 2016  
**IF(2015): 3.543**

39. Heise, T., Westrup, D., Jaeckel, E.:  
Praxisrelevante pharmakologische Eigenschaften von Insulin degludec.  
**Diabetes, Stoffwechsel und Herz** 25:171-179, 2016  
**IF(2015): 0.204**
40. Forst, T., Zijlstra, E.:  
Wie nah sind wir am artifiziellen Pankreas?  
**Info Diabetologie** 10(4): 36-40, 2016  
**IF(2015): -**
41. Forst, T., Jahnke, J.:  
Insulintherapie: Möglichkeiten, Grenzen, Entwicklungen.  
**Diabetes, Stoffwechsel und Herz** 25: 108-114, 2016  
**IF(2015): 0.204**
42. Forst, T., Zijlstra, E.:  
Glukoseselbstmessung – technische Möglichkeiten und Limitationen.  
**Diabetologie** 11: R52-R59, 2016  
**IF(2015): -**
43. Forst, T.:  
Kardiovaskuläre Effekte von Metformin, Sulfonylharnstoffen und Gliniden.  
**Diabetologie** 12: 162-170, 2016  
**IF(2015): -**
44. Forst, T.:  
Anti-diabetische Therapie und kardiovaskuläre Prognose. Kritischer Einsatz der Substanzen gefordert.  
**Diabetes aktuell** 13(7): 282-287, 2016  
**IF(2015): -**



## Letters / Comments

45. Zijlstra, E., Sawicki, P.T., Heise, T.  
Comment on Abdulreda et al. (Cell Metab. 23:541-546, 2016): Liraglutide compromises pancreatic beta cell function in a humanized mouse model.  
**Cell Metab.**, [http://www.cell.com/cell-metabolism/comments/S1550-4131\(16\)30001-8](http://www.cell.com/cell-metabolism/comments/S1550-4131(16)30001-8), March 2016  
**IF(2015): 17.897**

# Scientific Presentations

## Oral Presentations

### Global Scientific Expert Meeting. Zurich, Switzerland, December 8, 2016

46. Zijlstra, E.  
Reviewing the clinical pharmacology of faster aspart.
47. Natrass, M. (Facilitator), Russel-Jones, D., Sturis, J., Zijlstra, E.  
Panel Discussion.
48. Zijlstra, E.  
Reviewing the evidence of faster aspart during continuous insulin infusion.
49. Natrass, M. (Facilitator), Liebl, A., Philis-Tsimikas, A., Harris, S., Danne, T.,  
Zijlstra, E.  
Panel Discussion.

### 14. Düsseldorfer Diabetestag. Düsseldorf, Germany, November 24, 2016

50. Arnolds, S.  
Neue Forschungsansätze.
51. Heinemann, L.  
Neue Technologien.

### The World Congress on Clinical Trials in Diabetes. Berlin, Germany, November 30 – December 1, 2016

52. Forst, T.  
Tools and best practices to help clinical sites optimize performance and maintain compliance with GCP.
53. Forst, T.  
Study management – CRO vs in-house.

### Selbsthilfegruppe Rheinkreis Neuss, Grevenbroich, Germany, November 15, 2016

54. Arnolds, S.  
Neue Forschungsansätze.

**10. Herbsttagung der Deutschen Diabetes Gesellschaft. Nürnberg, Germany,  
November 11 – 12, 2016**

55. Forst, T.  
Lipo-Hypertrophien.  
Berufspolitisches Symposium des VDBD
56. Forst, T.  
Postprandiale Hyperglycaemie – klinische Folgen.  
Industriesymposium: Postprandiale Hyperglykämie – der vernachlässigte Zwilling  
der Diabeteseinstellung?
57. Forst, T.  
Update Insuline.  
DDG Symposium: Praxisrelevante Neuigkeiten zu modernen Antidiabetika
58. Forst, T.  
Übersicht Sulfonylharnstoffe – Gefahren, Kosten, Hospitalisation.  
DDG Symposium: Innovative und traditionelle Antidiabetika – Sicherheit für  
Patienten und Versorgungsrelevanz für Ärzte

**16. Annual Diabetes Technology Meeting. Bethesda, Maryland, USA, November, 10 – 22, 2016**

59. Heise, T.  
Novel rapid acting insulin analogs.  
Session: New drugs

**22<sup>nd</sup> Annual International Partnering Conference BIO-Europe. November 7 – 9, 2016**

60. Rütten, H. (Facilitator), Gram, D., Landh, T., Normand, A., Schliess, F.  
Lifestyle diseases and longevity.  
Panel Discussion

**Verband der Diabetes Beratungs- und Schulungsberufe. Mainz, Germany, November 5, 2016**

61. Forst, T.  
Drug-drug interactions in geriatric patients with diabetes mellitus type 2.

**German EIT Health Annual Symposium. Heidelberg, Germany, October 11, 2016**

62. Schliess, F.  
The CLOSE EIT Health innovation project by design: innovation of chronic  
homedcare for people with diabetes.



### Lilly. Taipeh, Japan & Hongkong, September 27 – October 5, 2016

63. Forst, T.  
What we have learned from update GLP-1 clinical research & experience on Truclicity.
64. Forst, T.  
Modern management of type 2 diabetes with GLP1 agonists.

### European Health Science Match. Heidelberg, Germany, September 26, 2016

65. Schliess, F.  
E-healing of diabetes – the artificial pancreas for at home.

### Kongress-Highlights Diabetologie: Konsequenzen für Klinik und Praxis. Berlin, Germany, September 24, 2016

66. Zijlstra, E., Forst, T.  
Diabetes-Technologien.

### Kongress-Highlights Diabetologie: Konsequenzen für Klinik und Praxis. Frankfurt/Main, Germany, September 23 2016

67. Zijlstra, E., Forst, T.  
Diabetes-Technologien.

### 52. EASD Annual Meeting. Munich, Germany, September 12 – 16, 2016

68. Andersen, G., Meiffren, G., Allius, B., Ranson, A., Soula, R., Gaudier, M., Soula, O., Kazda, C., Heise, T., Bruce, S.  
Ultra-rapid BioChaperone Lispro ameliorates postprandial blood glucose control compared to insulin lispro commercial formulation in subjects with type 1 diabetes mellitus.  
**Diabetologia** 59 (Suppl 1): S5 (7), 2016
69. Bruce, S., Heise, T., Hövelmann, U., Fischer, A., Nosek, L., Meiffren, G., Megret, C., Soula, R., Gaudier, M., Soula, O., Shaefer, C., Edelman, S.  
BioChaperone Combo (BC Combo) reduces post-prandial glucose in type 1 diabetes compared to conventional lispro mix 75/25 (LMx).  
**Diabetologia** 59 (Suppl 1): S400 (836), 2016
70. Zijlstra, E., Heise, T., Nosek, L., Rikte, T., Haahr, H.  
Faster-acting insulin aspart: faster offset of exposure and action in addition to faster onset in subjects with type 1 diabetes using continuous subcutaneous insulin infusion.  
**Diabetologia** 59 (Suppl 1): S98 (192), 2016.



**Trend Seminar “Digital innovation in diabetes care – opportunities and risks for patients, health care and economies”. Center for Digital Technology and Management, Munich, Germany, August 22 – October 7, 2016**

71. Heinemann, L.  
Introduction to diabetes.
72. Benesch, C.  
Technologies and sensors in metabolic closed loop systems.
73. Schliess, F.  
Automated glucose control at home for people with chronic disease.

**Verband der Diabetes Beratungs- und Schulungsberufe. Mainz, Germany, August 2, 2016**

74. Forst, T.  
New insulins.  
Testimonial Lecture

**Entrepreneurial Introductory Translational Research. Cologne, Germany, June 27 – July 1, 2016**

75. Schliess, F.  
Science and innovation in clinical contract research.

**ADA 76<sup>h</sup> Scientific Sessions. New Orleans, LA, June 10 – 14, 2016**

76. Andersen, G., Meiffren, G., Alluis, B., Ranson, A., Soula, R., Gaudier, M., Soula, O., Kazda, C., Heise, T., Bruce, S.  
Ultra-Rapid BioChaperone® Lispro ameliorates postprandial blood glucose (PPG) control compared with Humalog in subjects with type 1 diabetes mellitus.  
**Diabetes** 65 (Suppl. 1): 294-OR
77. Heise, T., Hövelmann, U., Fischer, A., Nosek, L., Alluis, B., Meiffren, G., Megret, C., Gaudier, M., Soula, O., Bruce, S., Shaefer, C., Edelman, S.V.  
BioChaperone® Combo (BC Combo) improves postprandial glycemia vs. Humalog® Mix 75/25™ (HMx) in people with type 1 diabetes mellitus (T1DM).  
**Diabetes** 65 (Suppl. 1): 295-OR

**Truclicity Launching Symposium, Korea, May 31 – June 3, 2016**

78. Forst, T.  
What benefit can truclicity provide to type 2 diabetes patients: clinical data & experience.

**Regional Innovation Network Diabetes. Düsseldorf, Germany, May 27, 2015**

79. Arnolds, S.  
Patienteninitiierte Forschung – welche Forschung wünschen sich Patienten mit Diabetes?

**Diabetes Expert Forum Scientific Exchange Meeting. Amman, Jordan, May 20 – 22, 2016**

80. Forst, T.  
Can weekly GLP-1 receptor agonists influence the current perspective of injectable therapies?
81. Forst, T.  
Understanding patient transition to injectable therapies.

**51. Jahrestagung der Deutschen Diabetes Gesellschaft. Berlin, Germany, May 4 – 7, 2016**

82. Heise, T.  
Postprandiale Blutzuckereinstellung – was ist die Zukunft?  
Industriesymposium: Postprandiale Blutzuckereinstellung bei Typ 2 Diabetes – warum, wie und was ist die Zukunft?
83. Heinemann, L.  
Neue Systeme für das kontinuierliche Glukosemonitoring.  
Diabetes-Technologie auf dem "Sprung" (AG Diabetes und Technologie der DDG).
84. Benesch, C.  
Automatische Bauchspeicheldrüse – wann kommt das erste Produkt?  
Diabetes-Technologie auf dem "Sprung" (AG Diabetes und Technologie der DDG).
85. Weissmann, J., Zijlstra, E.  
Eversense: Studienergebnisse.  
Industriesymposium.
86. Forst, T.  
Schnell wirksames, lang wirksames, oder gar kein Insulin ? Was ist die richtige Entscheidung beim Typ 2 Diabetes?  
Neue Trends in der Diabetestherapie (Arbeitsgemeinschaft niedergelassener diabetologisch tätiger Ärzte).
87. Forst, T.  
CGM in Deutschland – Konsens und Dissens.  
Update CGM und AGP (Symposium in memoriam Prof. Dr. med. Stephan Matthaei).

88. Heinemann, L.  
 Welche Angaben müssen Ärzte in den USA zu Geldzuwendungen machen und wann kommt das bei uns vor?  
 Conflict of interest: Zusammenarbeit mit der Industrie.  
 Vorsitz: Ziegler, R., Heinemann, L.
89. Heinemann, L.  
 Therapie des Typ 1 Diabetes – was bringen neue Technologien?  
 Fortbildung für Diabetesberater/-innen und Diabetesassistent/-innen „Aktuelle Trends der Diabetestherapie: Update 2016“.
90. Heinemann, L.  
 Vorgehen zu einer Verbesserung der Situation beim HbA1c und anderen Laborparametern  
 Symposium: HbA1c - kritische Neubetrachtung dieses zentralen Parameters in der Diabetologie (Kommission Labordiagnostik der Diabetologie der DDG und DGKL)
91. Heinemann, L. (Vorsitz)  
 Industriesymposium: Neue Wege der Steigerung des Therapieerfolgs - E-Adhärenz.
92. Forst, T. (Vorsitz)  
 Diabetische Neuropathie – Update 2016 (AG Diabetes und Nervensystem der DDG).

**Basagli Launch Meeting. Dubai, United Arab Emirates, May 14 – 15, 2016**

93. Forst, T.  
 Basagli clinical development program.
94. Forst, T.  
 Basagli: a new take on insulin glargine.

**Anwendertreffen DPV 2016. Sparkassenakademie Schloss Waldhausen, Mainz, Germany, April 22 – 23, 2015**

95. Weissmann, J., Zijlstra, E.  
 Senseonics implantierbares CGM: Erfahrungen der deutschen Patienten in der PRECISE-Studie.

**Imperial College London, Abu Dhabi and Dubai, United Arab Emirates, April 20 – 22, 2016**

96. Forst, T. Treatment with GLP-1 receptor antagonists



#### **Neuroimmunological Symposium. Leipzig, Germany, April 8, 2016**

97. Forst, T.  
Diabetes mellitus and its vascular dimension – myocardial infarction, stroke, and neuropathy.

#### **Grand Challenges: Answers from North Rhine-Westphalia. Innovation Pathways for Bioeconomic Solutions, Brussels, Belgium, April 7, 2016**

98. Schliess, F.  
The diabetes epidemic – impact of health innovations for patients and societies.

#### **Expert workshop. Frankfurt/Main, Germany, April 7, 2016**

99. Forst, T.  
German diabetology: today and in the future.

#### **Endocrine Societies 98th Annual Meeting and Expo. Boston MA, USA, April 1 – 4, 2016**

100. Heise, T., Stender-Petersen, K., Hövelmann, U., Jacobsen, J.B., Nosek, L.,  
Zijlstra, E., Haahr, H.  
Higher early insulin exposure and greater early glucose-lowering effect with faster-acting insulin aspart vs insulin aspart across a clinically relevant dose range.  
OR 12-6

#### **Speaker Tour Truclicity, Qatar & Kuwait, State of Qatar & State of Kuwait, March 4 – 7, 2016**

101. Forst, T.  
Truclicity: a new era in GLP-1 therapy.
102. Forst, T.  
Truclicity in the management of T2DM.

#### **Seminar on Intensified Conventional Insulin Therapy. Prien, Germany, March 11 – 13, 2016**

103. Forst, T.  
New insulins.

#### **German Diabetes Society (DDG). Freiburg, Germany, March 3, 2016**

104. Forst, T.  
Pharmacokinetics, galenics & molecular structure of insulins (training course).



**Diabetes #social: Mediendialog 2016. Mannheim, Germany, March 5 – 6, 2016,**

105. Zijlstra, E.  
Senseonics implantierbares CGM: Erfahrungen der deutschen Patienten in der PRECISE-Studie.

**9th International Conference on Advanced Technologies & Treatments for Diabetes.  
Milan, Italy, February 3 – 6, 2016**

106. Heise, T., Zijlstra, E., Rikte, T., Nosek, L., Haahr, H.  
Earlier onset of exposure and greater early pharmacokinetic and pharmacodynamic effects for faster-acting insulin aspart versus insulin aspart using continuous subcutaneous insulin infusion.  
**Diabetes Technol. Ther.** 18(S1): A-20, 2016
107. Zijlstra, E., DeHennis, A., Chen, X., Link, M.  
Rate of change accuracy assessment and lac time characterization of an implantable continuous glucose monitoring (CGM) system in the PRECISE study.  
**Diabetes Technol. Ther.** 18(S1): A-23, 2016

**Diabetology, Cardiology & Nephrology: Update 2016. Frankfurt/Main, Germany,  
February 20, 2016**

108. Forst, T.  
Cardiovascular risk factors, mechanisms & endpoint studies in type 2 diabetes: status quo?

**Winter Symposium for Diabetologists. Münster, January 29, 2016**

109. Forst, T.  
Pleiotropic effects of SGLT2 inhibitors.
110. Forst, T.  
HbA1c – the measure of all things?

**Dia.Tec 2016: Jahrestagung der AGDT und Fortbildung zur Diabetestechologie,  
Berlin, Germany, January 29 – 30, 2016**

111. Zijlstra, E.  
Überblick über die technologischen Ansätze.



**Kirchheim-Forum Diabetes. Berlin, Germany, January 22, 2016**

- 112. Forst, T.  
Therapy update – new insulins.
- 113. Forst, T.  
Meaningful blood glucose controls.

**Workshop “Basics of pharmacokinetic analyses” Novo Nordisk, Mainz, Germany, January 22 & 25, 2016**

- 114. Heise, T.  
Assessment of pharmacodynamics: insulin sensitivity and beta-cell function.

**Sanofi Berlin Symposium. Berlin, Germany, January 15, 2016**

- 115. Forst, T.  
Diabetology – more than managing blood glucose.



## Poster Presentations

### EIT Health Summit 2016, Barcelona, Spain, November 23 – 24, 2016

116. Schliess, F., Crône, V.  
CLOSE – automated glucose control at home for people with chronic disease.
117. Marcheal, D., Schliess, F.  
ClassIDM – integrated care for chronic diseases.

### 16. Annual Diabetes Technology Meeting, Bethesda, Maryland, USA, November 10 – 12, 2016

118. Benesch, C., Kuhlenkötter, M., Heise, T.  
A different design of glucose clamps: fixed rate of blood glucose change rather than fixed blood glucose levels.
119. Kuhlenkötter, M., Heise, T., Benesch, C.  
Minimal blood loss with automated glucose clamps: a new configuration of ClampArt.
120. Heise, T., Nørskov, M., Nosek, L., Kaplan, K., Famulla, S., Haahr, H.L.  
Insulin Degludec: four-times lower pharmacodynamic within-patient variability compared to insulin glargine U300 in type 1 diabetes.
121. Bailey, T., Dahmen, R., Pettus, J., Roussel, R., Bergmann, K., Maroccia, M., Nassr, N., Klein, O., Bolli, G., Heise, T.  
Insulin glargin 300 U/mL (Gla-300) provides more stable and more evenly distributed steady-state PK/PD profiles compared with insulin degludec in type 1 diabetes
122. Zijlstra, E., Chen, X., Masciotti, J.  
HbA1c estimation from a long-term continuous glucose monitoring system: comparison of different time windows.

### Canadian Diabetes Association Conference, Ottawa, Canada, October, 28 – 29, 2016

123. Heise, T., Pieber, T.R., Danne, T., Erichsen, L., Pakseresht, A., Haahr, H.  
Faster onset and greater early exposure and glucose-lowering effect with faster-acting insulin aspart vs. insulin aspart: a pooled analysis in subjects with type 1 diabetes.  
**Can. J. Diabetes** 40(5): S57, 2016



**11th International Diabetes Federation Western Pacific Region Congress & 8th Scientific Meeting of the Asian Association for the Study of Diabetes.  
Taipei, Taiwan, October 27 – 30, 2016**

124. Kapitza, C., Dahl, K., Jakobsen, J.B., Axelsen, M.B., Bergan, E.Q., Flint, A.  
The effects of once weekly semaglutide on beta-cell function in subjects with type 2 diabetes.  
PD 116

**52. EASD Annual Meeting. Munich, Germany, September, 12– 16, 2016**

125. Kapitza, C., Dahl, K., Jacobsen, J.B., Axelsen, M.B., Flint, A.  
The effects of once-weekly semaglutide on beta-cell function in subjects with type 2 diabetes.  
*Diabetologia* 59 (Suppl 1): S358 (754), 2016
126. Forst, T., Andersen, G., Falk, A., Plum-Mörschel, L., Fischer, A., Kapitza, C., Heise, T..  
Combination therapy with linagliptin and empagliflozin improves alpha- and beta cell function in patients with type 2 diabetes.  
*Diabetologia* 59 (Suppl 1): S373 (781), 2016
127. Link, M., Kropff, J., Choudhary, P., Neupane, S., Bain, S.C., Kapitza, C., Forst, T., Chen, X.O., DeVries, J.H.  
Implantable CGM with daily transmitter adhesive demonstrates high use compliance in a 180 day pivotal trial.  
*Diabetologia* 59 (Suppl 1): S422 (877), 2016
128. Meiffren, G., Hövelmann, U., Fischer, A., Klein, O., Maigret, C., Soula, R., Gaudier, M., Soula, O., Bruce, S., Cengiz, E., Heise, T..  
BioChaperone Combo, a co-formulation of lispro and glargin, demonstrates both prandial and basal insulin time-action profiles in a single injection in type 2 diabetes.  
*Diabetologia* 59 (Suppl 1): S5 (8), 2016
129. Kropff, J., Choudhary, P., Neupane, S., Bain, S., Kapitza, C., Forst, T., Link, M., DeHennis, A., DeVries, J.  
Accuracy and longevity of an implantable continuous glucose sensor in the precise study: a 180 day, prospective multi-centre pivotal trial.  
*Diabetologia* 59 (Suppl 1): S96 (187), 2016



**ADA 76<sup>th</sup> Scientific Sessions. New Orleans, LA, June, 10 – 14, 2016**

130. DeVries, J.H., Kropff, J., Choudhary, P., Neupane, S., Bain, S.C., Kapitza, C., Forst, T., Link, M., Dehennis, A.D.  
Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial.  
**Diabetes** 65 (Suppl. 1): 892-P, 2016
131. Choudhary, P., DeVries, J.H., Kropff, J., Neupane, S., Bain, S.C., Kapitza, C., Forst, T., Link, M., Rastogi, R., Chen, X.  
Glycemic benefits of a long-term implantable glucose sensor in the PRECISE study.  
**Diabetes** 65 (Suppl. 1): 908-P, 2016
132. Freude, S., Heise, T., Nordaby, M., Peil, B., Zeller, C., Wolff, M., Sabo, J.P., Vernillet, L., Woerle, H.J., Graefe-Mody, U.  
Safety and efficacy of BI 187004, a selective 11beta-hydroxysteroid dehydrogenase 1 (11b-HSD1) inhibitor after 4 weeks of treatment in patients with Type 2 Diabetes.  
**Diabetes** 65 (Suppl. 1): 1189-P, 2016
133. Andersen, G., Meiffren, G., Alluis, B., Ranson, A., Soula, R., Gaudier, M., Soula, O., Heise, T., Bruce, S.  
A pilot bioequivalence (BE) study of ultra-rapid concentrated BioChaperone Lispro (BCLIS) U200 to BCLIS U100.  
**Diabetes** 65 (Suppl. 1): P2242-PUB, 2016
134. Heise, T., Pieber, T.R., Danne, T., Erichsen, L., Haahr, H.  
Faster onset and greater early exposure and glucose-lowering effect with faster-acting insulin aspart vs. insulin aspart: a pooled analysis in subjects with type 1 Diabetes.  
**Diabetes** 65 (Suppl. 1): 929-P, 2016
135. Harris, C.J., Forst, T., Heise, T., Plum-Mörschel, L., Watkins, E., Fan, L., Garhyan, P., Porksen, N.K.  
Double dose (DD) of basal insulin peggispro (BIL) vs. glargin (GL) results in markedly lower incidence of hypoglycemia in patients with T2D: IMAGINE 8.  
**Diabetes** 65 (Suppl. 1): 936-P, 2016
136. Hövelmann, U., Fischer, A., Klein, O., Meiffren, G., Alluis, B., Megret, C., Gaudier, M., Soula, O., Bruce, S., Cengiz, E., Heise, T.  
Pharmacodynamic (PD) profile of BioChaperone® Combo (BC Combo), a new combination rapid-acting and long-acting insulin, in subjects with type 2 diabetes mellitus (T2DM)  
**Diabetes** 65 (Suppl. 1): 942-P, 2016

137. Famulla, S., Hövelmann, U., Nosek, L., Dowlat, H.A., Mehta, A., Heise, T.. Solumarv (SOLU), a regular human insulin, and Isomarv (ISO), a NPH-insulin preparation, show bioequivalence (BE) to EU-marketed insulins.  
**Diabetes** 65 (Suppl. 1): 956-P, 2016
- Nosek, L., Haahr, H., Heise, T., Hövelmann, U., Erichsen, L., Zijlstra, E., Stender-Petersen, K.  
Greater early glucose-lowering effect of faster-acting insulin aspart is observed consistently from day-to-day  
**Diabetes** 65 (Suppl. 1): 969-P, 2016
138. Ruan, Y., Thabit, H., Leelarathna, L., Hartnell, S., Wilinska, M.E., Dellweg, S., Benesch, C., Mader, J.K., Holzer, M., Kojzar, H., Evans, M.L., Arnolds, S., Pieber, T.R., Hovorka, R.  
Insulin pharmacodynamics and outcomes during home use of closed-loop insulin delivery in adults with type 1 diabetes.  
**Diabetes** 65 (Suppl. 1): 982-P, 2016
139. Kapitza, C., Dahl, K., Jacobsen, J.B., Axelsen, M.B., Flint, A.  
The effects of semaglutide on beta-cell function in subjects with type 2 diabetes.  
**Diabetes** 65 (Suppl. 1): 1012-P, 2016
140. Wysham, C., Bonadonna, R.C., Aroda, V., Domingo, M.P., Kapitza, C., Stager, W., Yu, C., Niemoeller, E., Souhami, E., Bergenstal, R., LIXILAN-L Trial Investigators.  
Efficacy and safety of LixiLan vs. insulin glargine according to baseline characteristics in patients with type 2 diabetes from the LixiLan-L trial.  
**Diabetes** 65 (Suppl. 1): 1018-P, 2016
141. Baughman, R.A., Heise, T., Grant, M.L., Grosjean, P., Perrin, L., Hijazi, Y., Goebel, B., Dahmen, R.  
Technosphere insulin inhalation powder (TI) displays earlier onset and shorter duration than insulin lispro (Lispro)  
**Diabetes** 65 (Suppl. 1): 100-LB, 2016

#### 51. Jahrestagung der Deutschen Diabetes Gesellschaft. Berlin, Germany, May 4 – 7, 2016

142. Hövelmann, U., Zijlstra, E., Stender-Petersen, K., Jacobsen, J.B., Heise, T., Haahr H.  
Schneller wirksames Insulin aspart (Faster aspart): Stärkere Insulinexposition und Wirkung innerhalb der ersten 2 Stunden auch bei älteren Menschen mit Typ 1 Diabetes (T1D).  
**Diabetologie & Stoffwechsel** 11: S36 (P126), 2016

- 143. Zijlstra, E., Heise, T., Rikte, T., Nosek, L., Haahr, H.  
 Schneller wirksames Insulin aspart (Faster aspart) versus Insulin aspart bei kontinuierlicher subkutaner Insulininfusion: schnellere initiale PK-Exposition und bessere pharmakokinetische und pharmakodynamische Wirkung in den ersten 2 Stunden.  
**Diabetologie & Stoffwechsel** 11: S34 (P120), 2016
  
- 144. Forst, T., Rohwedder, K., Sugg, J., Johnsson, E.  
 Dapagliflozin senkt den postprandialen Blutzucker ohne Anstieg von C-Peptid oder Insulin.  
**Diabetologie & Stoffwechsel** 11: S14 (P43), 2016

**Endocrine Societies 98<sup>th</sup> Annual Meeting and Expo. Boston MA, USA, April 1 – 4, 2016**

- 145. Zijlstra, E., Demissie, M., Graungaard, T., Heise, T., Nosek, L., Bode, B.W.  
 Compatibility and safety of faster-acting insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes.  
 FRI 697

**Update Diabetology, Cardiology & Nephrology 2016. Frankfurt/Main, Germany, February 20, 2016**

- 146. Forst, T.  
 Cardiovascular risk factors, mechanisms, and endpoint studies in type 2 diabetes: status quo?

**9th International Conference on Advanced Technologies & Treatments for Diabetes. Milan, Italy, February 3 – 6, 2016**

- 147. Hövelmann, U., Zijlstra, E., Stender-Petersen, K., Jacobsen, J.B., Heise, T., Haahr, H.  
 Higher early exposure and greater early glucose lowering effect with faster-acting insulin aspart vs insulin aspart in elderly and younger adults with type 1 diabetes (T1D).  
**Diabetes Technol. Ther.** 18(S1): A-44, 2016
  
- 148. Cohen, O., Andersen, G. Huang, S., Zijlstra, E., O'Sullivan, O., Welsh, J., Shin, J.  
 Accuracy of the continuous glucose sensor unsed with the predictive low glucose management system.  
**Diabetes Technol. Ther.** 18(S1): A-44, 2016
  
- 149. Zijlstra, E., Jahnke, J., Fischer, A., Kapitza, C., Forst, T.  
 Impact of injection volume, speed and site on pain sensation.  
**Diabetes Technol. Ther.** 18(S1): A-124, 2016



150. Zijlstra, E., Jahnke, J., Fischer, A., Kapitza, C., Forst, T.  
Backflow after drug injection: impact of injection volume, speed and site.  
**Diabetes Technol. Ther.** 18(S1): A-124, 2016



# Advanced Training Courses

## Science Sessions

### 151. **Prof. Dr. Thomas Forst**

Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany  
Diabetological endpoint trials.  
October 27, 2016

### 152. **Prof. Dr. Nanette Schloot**

Medical Director at Lilly Diabetes Germany, Austria and Switzerland, Bad Homburg, Germany & German Diabetes Research Center, Düsseldorf, Germany  
Autoimmunity, type 1 diabetes and LADA.  
September 29, 2016

### 153. **Prof. Dr. Lutz Heinemann**

Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany  
New diabetes technologies.  
August 31, 2016

### 154. **Dr. Daniela Lamers, Oliver Klein**

Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany  
Stable isotopes and doubly labeled water.  
June 30, 2016

### 155. **Prof. Dr. Ralf Lobmann**

Klinikum Stuttgart, Klinik für Endokrinologie, Diabetologie, und Geriatrie Stuttgart, Germany  
Diabetischer Fuß und diabetische Neuropathie.  
April 14, 2016

### 156. **Prof. Dr. Thomas Forst**

Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany  
Alpha- und Beta-Zelle bei Diabetes Mellitus.  
February 19, 2016



## Trainings with External Participants

### 157. DuET 2016 Düsseldorf Education on Trials

November 30 – December 1, 2016  
Profil, Neuss, Germany  
Novo Nordisk, Region Europe A/S

## DuET 2016 Clinical research and trials in diabetes



## Granted Research Consortia

### 158. EIT-Health e.V. and German EIT Health GmbH.

A knowledge and innovation community (KIC) on healthy living and active ageing, funded by the European Institute of Innovation and Technology (EIT).

First funding period: 2015 – 2022

<http://eithhealth.eu/>

Profil Neuss is EIT Health core partner.

EIT Health innovation project by design:

**Automated glucose control at home for people with chronic disease (CLOSE).**

Funding period: July 2016 – June 2020

Involved EIT Health partners: Air Liquide Healthcare, Sanofi, Profil Germany, IESE Business School, KU Leuven, Medical University of Lodz.

Additional project partners: Cellnovo, Aqua Institute for Applied Quality Improvement and Research in Health Care, Eurice, Forschungsverein Mechatronischer Systeme Linz

Coordinating organisation: Profil Germany



Members of the CLOSE Consortium.

CLOSE Consortia Meeting. IESE Business School Munich Campus, September 12, 2016



CLOSE & Center for Digital Technology and Management (CDTM) Trend Seminar "Digital Innovation in Diabetes Care". EIT Health Research Event. CDTM Munich, Germany, October 7, 2016

EIT Health innovation project by design

**Clinical validation of an interconnected disease management system for people with diabetes in Europe (ClassIDM).**

Funding period: January 2017 – December 2018

Involved EIT Health partners: Becton-Dickinson, Bull, Profil Germany, Université Grenobles Alpes.

Coordinating organisation: Becton-Dickinson

#### 159. Competence Center for Biomarker Research in Medicine.

COMET K1 Center for Biomarker Research at CBmed.

Funded by the Austrian Research Promotion Agency

First funding period: 2015 – 2019

<http://www.cbmed.org/en/index.php>

Profil Neuss is chairing the consortium board of the CBmed GmbH.

Profil Neuss is part of the project area "Metabolism & inflammation"

Project 3.6

Minimally invasive biomarkers for liver function.

Funding period: June 2015 – December 2018



160. **Regionales Innovationsnetzwerk (RIN) Diabetes.**

Funding: Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein Westfalen.

Funding period: 2014 – 2017

<http://www.rin-diabetes.de/>

161. **SPIDIMAN – Single-Port Insulin Infusion for Improved Diabetes Management.**

EU Project 7th Framework Programme, contract no. 305343

European Project to Combine Glucose Monitoring and Insulin Infusion in a Single Needle.

November 2012 – December 2016

<http://www.spidiman.eu/>

# Scientific Communication

## Webinars

<http://www.profil.com/knowledge-center/webinars>

162. **Pathogenesis and recent clinical developments in NASH.**  
F. Schliess, J. Schattenberg. December 1, 2016
163. **Reduced cost and time-to-market with ethno-bridging studies.**  
G. Andersen, August 25, 2016
164. **Incretin-based diabetes treatments.**  
Juris J. Meier. October 27, 2016
165. **Developing an Artificial Pancreas.**  
E. Zijlstra, C. Benesch. February 24, 2016
166. **Of mice and men: insulin sensitivity in preclinical and clinical trials.**  
T. Forst, T. Sulpice. April 14, 2016
167. **Diabetes: novel pathways - future treatments.**  
T. Forst, July 14, 2016
168. **Clinical development of insulin biosimilars.**  
T. Forst, November 26, 2016
169. **Alternative routes of insulin administration.**  
E. Zijlstra, May 13, 2016



## Blogs

<http://blog.profil.com/blog>

170. **Liver first? Part III: Medical needs and clinical trials in NAFL and NASH.**  
F. Schliess. December 9, 2016
171. **Liver first? Part II: NASH and NAFLD pathogenetic traits.**  
F. Schliess. December 1, 2016
172. **Modifying insulin kinetics - requirements and limitations. Part II: short acting insulins.**  
T. Forst. November 16, 2016
173. **Glucagon - the rising star in diabetes research. Part II: promising developments in new treatments for diabetes involving glucagon.**  
U. Hövelmann. October 21, 2016
174. **Profil scientists publish new clamp method to evaluate glucose measurement performance.**  
E. Zijlstra. September 27, 2016
175. **Glucagon - the rising star in diabetes research. Part I: a short history of glucagon.**  
U. Hövelmann. September 21, 2016
176. **TECOS study: no CVD risk or heart failure with sitagliptin in high-risk diabetes patients.**  
D. Lamers. September 14, 2016
177. **Medications for type 2 diabetes: a short historical perspective.**  
J. Arrubla. September 7, 2016
178. **Business trends in diabetes care: how should business models in the field of diabetes homecare in the future look like?**  
F. Schliess. August 24, 2016
179. **Modifying insulin kinetics - clinical requirements and limitations. Part I: long acting insulins.**  
T. Forst. August 10, 2016
180. **Liver first? Part I: The liver in diabetes and cardiovascular disease.**  
F. Schliess. July 20, 2016
181. **New review of hyperinsulinemic euglycemic glucose clamp technique.**  
L. Bochmann. July 1, 2016



182. **Addressing postprandial glucose excursion – what is the evidence?**  
T. Forst. June 15, 2016
183. **Walking the GIR-smoothing tightrope – data refinement versus data impairment.**  
K. Sondermann. June 1, 2016
184. **How to avoid selective reporting and publication bias?**  
S. Arnolds. May 11, 2016
185. **The new clinical trials regulation EU No 536/2014 - Update (05/2016).**  
G. Andersen. May 4, 2016
186. **Choosing markers of glycemic control during clinical trial design.**  
U. Hövelmann. April 13, 2016
187. **Understanding insulin resistance. Part II.**  
T. Forst. March 22, 2016
188. **Understanding insulin resistance. Part I.**  
T. Forst. March 16, 2016

## Media Reports (Selection)

189. **Auf die richtige Technik kommt es an.**  
FOCUS Diabetes, December 13, 2016
190. **Das Prinzip Hoffnung: Zuckerwächter im Taschenformat.**  
Diabetes Ratgeber, December 1, 2016
191. **Neues Insulin gegen Blutzuckerspitzen ante portas.**  
Ärzte Zeitung, November 28, 2016
192. **Wachsende Evidenz für Insulin Glargin U300.**  
Medical Report, November 23, 2016
193. **Tresiba demonstrated a lower day-to-day and within-day variability in glucose lowering effect compared with insulin glargine U300.**  
[www.pr21.de](http://www.pr21.de), November 12, 2016
194. **Insulin: ultraschnelle Wirkung gefragt.**  
Ärzte Zeitung, October, 26, 2016
195. **EIT Health Trend Seminar 2016 at CDTM: Digital Innovation in Diabetes Care.**  
eithhealth.eu, October 12, 2016
196. **Forschung hilft heilen.**  
Diabetes LIVING, October 1, 2016
197. **Diabetesforschung: helfen Sie mit.**  
PfalzSpiegel Kusel October 1, 2016
198. **Insulintherapie: wir sollten Patienten mehr zutrauen.**  
Ärzte Zeitung, September 19, 2016
199. **Adocia to present clinical data validating BioChaperone® Technology at the 2016 EASD annual meeting.**  
[www.wallstreet-online.de](http://www.wallstreet-online.de), September 9, 2016
200. **Forschung für mehr Lebensqualität**  
Diabetologie-online, September 5, 2016



Svenja Schulze, the Minister of Innovation, Science, and Research of the federal state North Rhine-Westphalia visited Profil Germany on August 22, 2016.

201. **Beispielhaftes Engagement für mehr Lebensqualität:  
NRW Wissenschaftsministerin Svenja Schulze besuchte  
Stoffwechselforschungsinstitut Profil in Neuss.**  
DiabSite, September 4, 2016
202. **Mit Forschung das Leben von Diabetikern erheblich verbessern.**  
Diabetes Journal, September 1, 2016
203. **Tour trotzt Diabetes.**  
Diabetes News, September 1, 2016
204. **Ministerin besucht Institut in Neuss.**  
[www.rp-online.de](http://www.rp-online.de), August 27, 2016
205. **Ministerin besucht Institut in Neuss: Profil Institut für Stoffwechselforschung zeigt Stand der Diabetesforschung**  
Neuss-Grevenbroicher Zeitung, August 27, 2016
206. **“Tour de Diabetes”: Patienten mit Typ 1 und Typ 2 Diabetes radelten durch Deutschland.**  
Diabetes Zeitung August 24, 2016
207. **Diabetes Selbstmanagement: Therapie undenkbar ohne Schulung.**  
[www.diabetes-online.de](http://www.diabetes-online.de), August 10, 2016
208. **Proband werden - und selbst profitieren.**  
Nordbahn-Nachrichten, July 3, 2016
209. **Neue Optionen für bessere BZ Kontrolle.**  
Ärzte Zeitung, June 27, 2016



210. **In-house Projekt zur Qualifizierung für Diabetes Studien. Weiterbildung: Profil Institut setzt bei "Study Nurse" Schulung auf IHK Hilfe.**  
IHK magazin Mittlerer Niederrhein, June 1, 2016
211. **Die Stechhilfe – das unbekannte Wesen.**  
[www.diabetes-online.de](http://www.diabetes-online.de), May 3, 2016
212. **German CLC organised first national Campus Workshop.**  
eithhealth.eu, April 15, 2016
213. **Erfolgreiche Evaluation eines subkutan implantierten Glucosesensors.**  
Info Diabetologie, April 1, 2016
214. **Hypoglycaemie. Angst fressen Seele auf.**  
MedWelt – Die Medizinische Welt, February 1, 2016
215. **Höher konzentriertes Basalinsulin mit verringertem Hypoglykämierisiko.**  
Medical Tribune, January 22, 2016
216. **Free webinar “Developing an Artificial Pancreas” hosted by EIT Health core partner Profil Germany.**  
eithhealth.eu, January 15, 2016